Most scientists are becoming aware that KO mice often develop cellular compensatory mechanisms that can 'muddy' the predicted results. This problem is often compounded because many physiologists and molecular biologists do not understand how different even the mouse and rat cardiovascular systems are, let alone mouse versus man.
D espite the above caveat, the impressive new technology described by Gupta et al 1 in this issue of Circulation: Cardiovascular Imaging should help to resolve a number of issues relative to the hypothesis that the failing heart is energy starved and that depressed high-energy phosphate flux through the creatine kinase (CK) system is a causative factor. 2, 3 It will allow longitudinal measurements of CK kinetics during the progression to failure in wild-type and transgenic mice with systematically varied amounts of each component of the CK system. Despite years of research, the importance of the several CK isoforms in myocardial bioenergetics is not clear. CK substrates (total creatine, total adenylates) and enzyme activity typically are depressed in heart failure in both murine and human hearts, contributing to the hypothesis that the failing heart is energy starved. However, knockout of myofibrillar (MM) CK and of both MM and sarcomeric mitochondrial CK isoform has surprisingly little effect: Animals are viable, and cardiac function is relatively normal. Thus, there is no obligatory creatine phosphate (PCr) shuttle where high-energy phosphates generated by mitochondrial oxidative phosphorylation must be transported to the myofibrils by way of PCr. Nevertheless, the evolutionary preservation of the complex myocardial CK system speaks to its importance, and the correlation between derangements in this system and contractile dysfunction is intriguing.
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It appears that despite the massive difference in size and resting rate between murine and human hearts, the rate of ATP synthesis (Ϸ3 mol/g per second) through CK, the primary myocardial energy reserve, is remarkably similar per gram between these species. Long-standing pressure overload and heart failure induced by thoracic aortic constriction results in an Ϸ30% reduction in kf and an Ϸ50% decline in the rate of ATP synthesis through CK. The reduction in ATP flux through CK is much greater than the reduction in the PCr/ATP ratio or [ATP], suggesting that the previously used indices of myocardial energetics based on metabolite pool sizes underestimate the reduction in myofibrillar ATP delivery in failing hearts. Furthermore, the 50% reduction in ATP flux through CK observed here in the in vivo failing thoracic aortic constriction mouse heart is similar to the 50% reduction in patients with dilated cardiomyopathy and the 65% reduction in patients with pressure overload hypertrophy and heart failure, suggesting that this murine model mimics important bioenergetic aspects of human heart failure.
It must be remembered, however, that all of the CK isoforms catalyze a freely reversible reaction, bringing CK reactants, ATP, ADP, PCr, H ϩ , and creatine to thermodynamic equilibrium. In fact, forward CK activity as measured by 31 P nuclear magnetic resonance in isolated wild-type mouse hearts exceeds the rate of ATP production by a factor of 6.
Thus, CK flux may not necessarily reflect rates of highenergy phosphate production and utilization, and the extent to which the rate of localized ADP phosphorylation by PCr affects myofibrillar dynamics in vivo remains to be established. The elegant new methodology described by Gupta et al 1 will go a long way toward clarifying this issue. 4, 5 Small rodents, including mice (Mus musculus), are used in Ͼ95% of animal experiments, 6 the results of which are intended for use in man (Homo sapien). Although a great deal of information obtained from studies on infrahuman mammals has been extrapolated-apparently successfully-to man, we are challenged by animal rights advocates, by laboratory animal care and use committees, by funding agencies, and by clinical investigators to know how anatomic, physiological, and genetic similarities or differences between infrahuman mammals and man might affect the appropriateness of the extrapolations. Indeed, as different as the outward appearances are between mice and man, it is not surprising that there should be markedly different physiologies as well. In this epoch of genetic engineering for which the mouse appears to be well suited and because they are relatively inexpensive to purchase and to house, there is a particular need for information on cardiac electrophysiology, mechanics, biochemistry, and synthesis of mechanics with biochemistry (termed myocardial energetics 7 ) in the mouse and to be convinced that information obtained from experiments on mice is applicable to the target species, man. Is the mouse merely a small human being? 8 Are all (even wild-type) mice alike? Symmorphosis 9 says that structure and physiology are "designed" to meet-not to exceed-maximal metabolic requirements. Behavior, with its attending metabolic requirement that must be subserved by cardiovascular function, varies greatly between mice and man. Mice are genetically "tuned" to the fact that they are gatherers and that they move very slowly over relatively short distances, except when threatened they run explosively for short distances. Man, on the other hand, is tuned to be a hunter-gatherer who moves over rather great distances and runs less explosively but for much greater distances. One may argue that man is no longer a hunter-gatherer in most present societies; however, our genotype evolving slowly from 1 ⁄4 million years ago has not had time to change to "serve" our rapidly changing social behavior and ecology.
It is well-known that many physiological and energetic properties depend on the relative abundance of the 3 myosin heavy chain isoforms: V1, V2, and V3. 10, 11 In general, dominance of the V1 isomer, seen in mice, is associated with high ATPase activities, high crossbridge turnover rates, and high resting heart rates in contrast with the essentially pure V3 isomer found in humans, where the resting heart is much slower. It is well-known that changes in the myosin isoform occur with age and hypertrophy and that such changes produce distinct mechanical and energetic changes. In the era of a search to improve ventricular contraction without risk of arrhythmia or production of negative energy balance, therapeutic agents are being developed that improve molecular motors without increasing demand of energy from ATP (ie, increased efficiency of ATP utilization). 12, 13 Thus, it is not surprising that cardiovascular function, including myocardial energetics, should be tuned for different missions in mice and man.
Of course, there are many quite obvious similarities between mice and man: both are omnivorous; males war often to the death; both are terrified of rats; both have 4-chambered hearts; both hearts are Ϸ0.5% of body weight; both right atrial and mean systemic arterial pressures are, respectively, 5 mm Hg and 100 mm Hg; and both have erythrocytes and capillaries approximately 6 m in diameter to mention a few. However, enormous differences exist between mice and man, and these differences cannot be explained by simple allometric scaling. Based on scaling or dimensional arguments, 8, 9, 14 one might expect mouse cardiac tissue to have an in vivo basal rate of approximately 40 mW/g and predict that human cardiac tissue will have an in vivo rate of approximately 5 mW/g, which is an approximate 8-fold difference. 10, 11 Mice never vomit and live 2 to 3 years; man lives 75 to 85 years. At mice thermoneutrality (also their thermopreferendum), their hearts beat approximately 350/min; heart rate in man is approximately 70/min. Possibly all physiology, pathophysiology, pharmacology, and toxicology studied using "chilled" mice should be repeated on mice raised at their thermoneutrality because information gleaned from mice is extrapolated to man studied and treated at man's thermoneutrality. 15 In their life span, the mouse heart (like hearts from all other mammals except man and cat) achieves 700 million heart beats; cat achieves 1.2 billion and man, 2.5 billion. Ion channels specific for genesis of the ventricular myocardial action potential, and pervasive distribution of Purkinje fibers, subserve the rapid rate of mice. Both mechanical and electrophysiological diastolic reserves for the mouse are tuned to their sedentary lifestyle; durations of isovolumetric contraction time plus left ventricular ejection time leave little time for diastasis, and the QT:TQ leaves little time for restitution (ie, limited repolarization reserve). And of great importance, mice-but not man-possess the physiology of torpor (a state in which their metabolic rate can be reduced drastically). Of course, the human heart "hibernates," 16 but physiology of this hibernation is quite distinct from the physiology of torpor. 17 It is thought that the 8-fold greater metabolic rate of mice compared to man may be explained by the differences in heart rates. When that number is corrected by the fact that the mouse, at its thermoneutrality, has a heart rate of approximately 350/min (not the 600/min present because mice are housed at 10°C below their thermoneutrality), the difference in heart rates is not 8-fold, but only 5-fold. Furthermore, the energy per beat for the mouse heart is only 6 mJ/g, whereas it is 16 mJ/g for the human heart, almost 3 times greater. The similarity reported in this article between rates of ATP synthesis (3 mol/L per gram per second) in mice and man can only be reconciled with the energy transfer per beat being one third as great in mice as in man by differences in efficiency.
We have not addressed how this work may guide future clinical investigations, particularly with respect to contemporary cardiac spectroscopy (cMRS) technical developments. Given the present availability of comparable cMRS techniques for in vivo human studies of myocardial metabolism, this work is a pivotal step and can usher in a new era of understanding impaired energetics in mouse models of heart failure. Such studies, in turn, will surely facilitate development of novel heart failure prevention and treatment strategies informed by a refined appreciation of CK flux in the failing heart.
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